Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada Approves (Pr)AFINITOR* in Advanced Breast Cancer for Women Battling This Disease Français


News provided by

Novartis Pharmaceuticals Canada Inc.

Jan 16, 2013, 08:25 ET

Share this article

Share toX

Share this article

Share toX

  • Approval represents a development for Canadian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer since aromatase inhibitors were introduced almost 15 years ago1
  • In a landmark study of 724 patients randomized to receive either the combination of AFINITOR* plus exemestane or placebo plus exemestane, there was a statistically significant clinical benefit of AFINITOR*  plus exemestane by more than doubling median progression-free survival2
  • AFINITOR*, the first mTOR inhibitor approved for HR+, HER2-negative advanced breast cancer, is given after the disease progresses following prior therapy with letrozole or anastrozole2

DORVAL, QC, Jan. 16, 2013 /CNW/ - Novartis Canada today announced that Health Canada has approved AFINITOR* (everolimus) tablets for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.3

"Everolimus is the first in a new class of treatment to overcome resistance to endocrine therapy," said Dr. Sunil Verma, Canadian Medical Oncologist. "The approval of everolimus has the potential to redefine the way we treat hormone receptor-positive advanced breast cancer, and offers physicians and patients a new therapeutic option where there remains a significant need."

In Canada, an estimated 22,700 women were diagnosed with breast cancer in 2012.4 Of those newly diagnosed patients, approximately 10 per cent will have locally advanced and/or metastatic disease and 20 to 85 per cent of patients, depending on the initial stage, tumour biology, and treatment strategy used, who are diagnosed with early breast cancer will later develop recurrent and/or metastatic disease.5 Advanced breast cancer is currently considered an incurable disease. It is estimated that women with metastatic breast cancer have a life expectancy of approximately 18-36 months after diagnosis,6 and median survival for women with stage III disease is less than five years.7

Diagnosed with metastatic breast cancer in 2012, Susan Cooper knows first-hand what it's like to live with the disease.

"Advanced breast cancer has changed the way I look at life. Time is so precious. I try to make the most of every day and not let my cancer stop me from doing the things I love to do, like spending time with my grandchildren," said Susan. "My hope is that new treatments will help others live longer without their cancer getting worse, while allowing them to enjoy the time they have left."

For women with HR+, HER2-negative advanced breast cancer, endocrine therapy remains the cornerstone of treatment, but most will eventually develop resistance to this therapy.2 Approximately 50 per cent of HR+ breast cancer patients with metastatic disease do not respond to initial treatment with hormone therapy, and almost all initial responders develop resistance.8 This therapeutic resistance has been associated with overactivation of the PI3K/AKT/mTOR pathway.2 AFINITOR* targets the mTOR pathway, which is dysregulated in the majority of human cancers. mTOR is a protein that plays a central role in the regulation of cell growth, proliferation and survival3.

"Women living with metastatic breast cancer have unique needs that differ from those living with primary disease. In addition to much-needed programs and services to support these women, access to new treatments is crucial in battling this incurable, yet treatable, form of breast cancer," said Cathy Ammendolea, Chair, Canadian Breast Cancer Network.

About Advanced Breast Cancer
Hormone receptor-positive, HER2-negative advanced breast cancer (HR+, HER2-negative advanced breast cancer) is comprised of metastatic breast cancer (stage IV) and locally advanced breast cancer (stage III).9 Metastatic breast cancer is the most serious form of the disease and occurs when the cancer has spread to other parts of the body, such as the bones or liver.9 Locally advanced breast cancer occurs when the cancer has spread to lymph nodes and/or other tissue in the area of the breast, but not to distant sites in the body.10

HR+ breast cancer is characterized by hormone receptor tumours, a group of cancers that express receptors for certain hormones, such as estrogen and progesterone. Cancer cell growth can be driven by these hormones.9 The presence of estrogen receptor (ER) and/or progesterone receptor (PgR) is one of the most important predictive and prognostic markers in human breast cancers, and is collectively referred to as hormone receptor-positive (HR+).

About AFINITOR*
AFINITOR* tablets are approved in more than 80 countries, including Canada, for the treatment of well- or moderately differentiated neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease that has progressed within the last 12 months the treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell morphology, after failure of initial treatment with either of the VEGF-receptor TKIs1 sunitinib or sorafenib. To date, approximately 45,500 patients have been treated with everolimus worldwide across other approved indications.

Health Canada approval of AFINITOR* in HR+, HER2-negative advanced breast cancer was based on a randomized, double-blind, multi-center Phase III study of AFINITOR* plus exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive, HER2-neu/non-amplified breast cancer with recurrence or progression following therapy with letrozole or anastrozole.

In the landmark study called BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), a total of 724 patients were randomized to receive either the combination of everolimus (10 mg daily) plus exemestane (25 mg daily) or placebo plus exemestane arm. This pivotal study demonstrated a statistically significant clinical benefit of everolimus plus exemestane over placebo plus exemestane by more than doubling median progression-free survival (PFS) (median: 7.36 months versus 3.19 months).3

The most common adverse events (incidence ≥ 30%) were stomatitis, infections, rash, fatigue, diarrhea and decreased appetite. The most common grade 3-4 adverse events (incidence ≥ 3%) were stomatitis, infections, fatigue, dyspnoea and pneumonitis.2,3,11

To help patients access AFINITOR*, Novartis Pharmaceuticals Canada Inc. (Novartis Oncology) is offering a patient support program called AfiniTRACTM. The AfiniTRACTM program pursues coverage options for patients and may provide financial assistance, in some cases, for qualified patients. In addition, when registering into the program, patients will receive a Patient Starter Kit which includes a booklet on managing their disease and understanding the possible side effects associated with treatment, as well as sample products that can help with the management of treatment. For more information about this program, patients are encouraged to call the AfiniTRAC™ hotline at 1-888-6AFINITOR.
_________________________________________
*VEGF receptor TKIs = vascular endothelial growth factor receptor tyrosine kinase inhibitors

About Novartis Oncology
Novartis Oncology has advanced the treatment of patients with breast cancer across the disease continuum. In addition to developing medicines that are specifically aimed at breast cancer, Novartis is a leader in seeking to improve outcomes for cancer patients, having brought to market the first medical therapy for the treatment of patients with bone complications associated with advanced malignancies, PrAREDIA* (pamidronate disodium), more than 20 years ago.

Since then, Novartis Oncology has a proven track record of discovering and developing therapies that aim to change the way patients live with various types of cancer. The company's commitment to breast cancer patients is demonstrated by PrFEMARA* (letrozole) and PrZOMETA* (zoledronic acid).

For more than 20 years, Novartis Oncology has helped pave the way for significant advances in the treatment of patients with breast cancer. The company's research priorities are determined by patient need and disease understanding. Novartis Oncology's research strategy is to identify the structure of a tumour and the molecular pathways of the disease to develop targeted medicines that address the unmet medical needs of patients.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

*AFINITOR, AREDIA, FEMARA, and ZOMETA are registered trademarks.

References
_____________________________________

1 Redmond C. Breast Cancer Hormone Therapy Options. Available at: http://suite101.com/article/breast-cancer-hormone-therapy-options-a197304 Accessed April 27, 2012.
2 Baselga J. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine. February 9, 2012.
3 AFINITOR* Product Monograph.
4 Canadian Cancer Society. Breast cancer statistics at a glance. Available at: http://www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/stats%20at%20a%20glance/breast%20cancer.aspx. Accessed June 4, 2012.
5 Bernard-Marty C.  Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer. The Oncologist. 2004;9:617-632. Available at: http://theoncologist.alphamedpress.org/content/9/6/617.full. Accessed June 4, 2012.
6 Eniua A, Palmierib F and Perez E. Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer. The Oncologist, 2005.
7 Giordano S. Update on Locally Advanced Breast Cancer. The Oncologist, 2003.
8 Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
9 National Cancer Institute. What You Need to Know About Advanced Breast Cancer. Available at: http://www.cancer.gov/cancertopics/wyntk/breast/WYNTK_breast.pdf. Accessed on March 8, 2012.
10 Hortobagyi, GN. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. SABCS 2011. November 8, 2011.
11 Piccart, Martine. Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. Poster #559. American Society of Clinical Oncology Annual Meeting.

SOURCE: Novartis Pharmaceuticals Canada Inc.

Celeste Brown
External Communications, Novartis Pharmaceuticals Canada Inc.
(514) 631-6775 ext. 1033
[email protected]

Amanda Federchuk
Consultant, GCI Group (416) 486-7231
[email protected]

Modal title

Organization Profile

Novartis Pharmaceuticals Canada Inc.

    Also from this source

  • Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada

  • Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

  • The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.